drugset / Trial / NCT03393026

A Study of Lurasidone HCl in Subjects With Schizophrenia

NCT03393026

Phase 4 Completed 54 enrolled Standard Chem. & Pharm. Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study evaluates the effectiveness and safety of Lurasidone in subjects with schizophrenia over a period of 6 weeks.

Timeline

Start
2018-01-03
Primary completion
2019-09-17
Completion
2019-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 160 mg Oral

Indications